Bicycle Therapeutics (BCYC) EBT Margin (2018 - 2026)
Bicycle Therapeutics' (BCYC) quarterly EBT Margin came in at 7987.76% in Q2 2026, down 527601.0% YoY from N/an in Q2 2025, and down 16.81% on a QoQ basis from 6837.99% in Q1 2026.
Bicycle Therapeutics (BCYC) EBT Margin (2018 - 2026) Analysis & Trends
Bicycle Therapeutics (BCYC) has 9 years of EBT Margin data on file, last reported at 7987.76% in Q2 2026.
- Quarterly EBT Margin fell 527601.0% year-over-year to 7987.76% in Q2 2026, while the trailing twelve-month figure through Jun 2026 was 319.14% (up 99835.0% YoY) and the FY2025 annual result came in at 310.61%, up 19857.0% from the prior year.
- EBT Margin declined to 7987.76% in Q2 2026, from 6837.99% in the prior quarter.
- In the past five years, EBT Margin ranged from a high of 53.25% in Q4 2025 to a low of 7987.76% in Q2 2026.
- A 5-year average of 1580.42% and a median of 767.72% in 2023 frame the typical range for EBT Margin.
- Annual changes were most pronounced in 2025 — EBT Margin soared 153116 bps — and 2026, when it plunged 621816 bps.
- Tracing BCYC's EBT Margin over 5 years: stood at 386.1% in 2022, then plunged by 155 bps to 985.78% in 2023, then plunged by 61 bps to 1584.41% in 2024, then soared by 97 bps to 53.25% in 2025, then tumbled by 14900 bps to 7987.76% in 2026.
- The last three EBT Margin figures came in at 7987.76% (Q2 2026), 6837.99% (Q1 2026), and 53.25% (Q4 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 41.75% |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 35.61% |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 34.77% |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 18.33% |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -94.22% |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 12.09% |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 13.77% |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -2.67% |
| 10 | Bicycle Therapeutics | 272.28 Mn | 272.28 Mn | - | -7,987.76% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -7,987.76% |
| Mar 31, 2026 | -6,837.99% |
| Dec 31, 2025 | 430.75% |
| Sep 30, 2025 | -501.92% |
| Jun 30, 2025 | -2,711.75% |
| Mar 31, 2025 | -619.84% |
| Dec 31, 2024 | -1,427.62% |
| Sep 30, 2024 | -2,027.28% |
| Jun 30, 2024 | -424.07% |
| Mar 31, 2024 | -258.78% |
| Dec 31, 2023 | 2,517.37% |
| Sep 30, 2023 | -889.87% |
| Jun 30, 2023 | -378.35% |
| Mar 31, 2023 | -810.50% |
| Dec 31, 2022 | -386.10% |
| Sep 30, 2022 | -940.30% |
| Jun 30, 2022 | -514.62% |
| Mar 31, 2022 | -724.95% |
| Dec 31, 2021 | -1,174.06% |
| Sep 30, 2021 | -348.33% |